Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Protagonist Therapeutics, Inc. (PTGX : NSDQ)
 
 • Company Description   
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Number of Employees: 126

 
 • Price / Volume Information   
Yesterday's Closing Price: $51.05 Daily Weekly Monthly
20 Day Moving Average: 983,848 shares
Shares Outstanding: 61.98 (millions)
Market Capitalization: $3,164.18 (millions)
Beta: 2.26
52 Week High: $60.60
52 Week Low: $32.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.15% -10.28%
12 Week 24.85% 4.74%
Year To Date 32.25% 23.88%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7707 GATEWAY BLVD. SUITE 140
-
NEWARK,CA 94560
USA
ph: 510-474-0170
fax: -
info@ptgx-inc.com http://www.protagonist-inc.com
 
 • General Corporate Information   
Officers
Dinesh V. Patel - President; Chief Executive Officer and Director
Harold E. Selick - Chairman
Asif Ali - Executive Vice President; Chief Financial Officer
Bryan Giraudo - Director
Sarah O'Dowd - Director

Peer Information
Protagonist Therapeutics, Inc. (CORR.)
Protagonist Therapeutics, Inc. (RSPI)
Protagonist Therapeutics, Inc. (CGXP)
Protagonist Therapeutics, Inc. (BGEN)
Protagonist Therapeutics, Inc. (GTBP)
Protagonist Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74366E102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 61.98
Most Recent Split Date: (:1)
Beta: 2.26
Market Capitalization: $3,164.18 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.05 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 68.07
PEG Ratio: -
Price Ratios
Price/Book: 4.59
Price/Cash Flow: 11.30
Price / Sales: 15.23
EPS Growth
vs. Year Ago Period: -105.83%
vs. Previous Quarter: -109.60%
Sales Growth
vs. Year Ago Period: -88.89%
vs. Previous Quarter: -83.40%
ROE
06/30/25 - -
03/31/25 - 9.22
12/31/24 - 47.67
ROA
06/30/25 - -
03/31/25 - 8.31
12/31/24 - 42.46
Current Ratio
06/30/25 - -
03/31/25 - 17.25
12/31/24 - 12.48
Quick Ratio
06/30/25 - -
03/31/25 - 17.26
12/31/24 - 12.48
Operating Margin
06/30/25 - -
03/31/25 - 27.04
12/31/24 - 63.34
Net Margin
06/30/25 - -
03/31/25 - 27.04
12/31/24 - 63.34
Pre-Tax Margin
06/30/25 - -
03/31/25 - 27.47
12/31/24 - 64.32
Book Value
06/30/25 - -
03/31/25 - 11.12
12/31/24 - 11.33
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©